Marion Carafate advertising
The company met with FDA Division of Drug Advertising and Labeling on April 10 to discuss remedial actions that the agency requested in a March 14 reg letter. In objecting to Marion's continuing promotions that imply that Carafate is useful for NSAID-induced ulcers and other unapproved uses. FDA told the firm that it should send a corrective letter to every U.S. physician and run corrective ads in medical journals ("The Pink Sheet" March 27, p. 9).
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.